Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Go back to Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML| (NASDAQ: APVO) | Delayed: 1.82 -0.01 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.83 | 52 Week High | $4.33 | |||
| Open | $1.83 | 52 Week Low | $1.80 | |||
| Day High | $1.92 | P/E | N/A | |||
| Day Low | $1.80 | EPS | $0.00 | |||
| Volume | 45,092 | |||||
